Table 2.
HSV-1 Incidence According to Treatment Arm, PrEP Intake, and Results of HSV-2 Serology at Baseline: The ANRS Ipergay Trial
| Variable | Total | Treatment | Number of Pills/Montha (TDF/FTC Arm) | HSV-2 Serology at Baseline | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 108 | TDF/FTC n = 53 |
Placebo n = 55 |
HR (95% CI) |
P | ≤15 n = 28 |
> 15 n = 24 |
HR (95% CI) |
P | Negative n = 69 |
Positive n = 39 |
HR (95% CI) |
P | |
| HSV-1 incidence, per 100 PY 95% CI |
11.7 [6.4–19.6] |
16.2 [7.4–30.8] |
7.8 [2.5–18.2] |
2.08 (0.63–7.92) |
.19 | 20.6 [7.6–44.9] |
11.5 [2.4–33.6] |
1.80 (0.38–11.10) |
.43 | 15.6 [7.8–27.9] |
6.1 [1.3–17.9] |
2.55 (0.67–14.23) |
.14 |
Abbreviations: CI, confidence interval; FTC, emtricitabine; HR, hazards ratio; HSV, herpes simplex virus; PrEP, pre-exposure prophylaxis; PY, person-years; TDF, tenofovir disoproxil fumarate.
aOne missing data.